Scarica l'app Stockscreener
7.40
0.00%
0.00
Dopo l'orario di chiusura:
7.37
-0.03
-0.41%
Precedente Chiudi:
$7.40
Aprire:
$7.36
Volume 24 ore:
53,415
Relative Volume:
0.98
Capitalizzazione di mercato:
$54.55M
Reddito:
$7.00M
Utile/perdita netta:
$-56.03M
Rapporto P/E:
-0.9662
EPS:
-7.6589
Flusso di cassa netto:
$-51.79M
1 W Prestazione:
+16.54%
1M Prestazione:
+4.67%
6M Prestazione:
+90.23%
1 anno Prestazione:
+60.87%
Intervallo 1D:
$7.35
$7.55
Intervallo di 1 settimana:
$6.08
$7.55
Portata 52W:
$3.5334
$7.55
Kezar Life Sciences Inc Stock (KZR) Company Profile
Nome
Kezar Life Sciences Inc
Settore
Industria
Telefono
650-822-5600
Indirizzo
4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare KZR vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KZR
Kezar Life Sciences Inc
|
7.40 | 54.55M | 7.00M | -56.03M | -51.79M | -7.6589 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Kezar Life Sciences Inc Stock (KZR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-17 | Downgrade | Jefferies | Buy → Hold |
| 2025-10-17 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-08-11 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-03-16 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2021-12-08 | Iniziato | Wells Fargo | Overweight |
| 2018-07-16 | Iniziato | Jefferies | Buy |
| 2018-07-16 | Iniziato | Wells Fargo | Outperform |
| 2018-07-16 | Iniziato | William Blair | Outperform |
Mostra tutto
Kezar Life Sciences Inc Borsa (KZR) Ultime notizie
Kezar Life Sciences shares surge after Aurinia announces acquisition - MSN
Aurinia Pharmaceuticals acquiring Kezar Life Sciences - MSN
Kezar Life Sciences Announces Lease Termination and Executive Separation Agreements in April 2026 - Minichart
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.96 Per Share Plus Contingent Value Rights in 2026 Merger Deal - Minichart
KZR PE Ratio & Valuation, Is KZR Overvalued - Intellectia AI
Kezar Life Sciences announces lease termination and executive departures following merger agreement - ca.investing.com
Kezar Life Sciences Announces Major Executive Leadership Changes - tipranks.com
Aurinia Pharmaceuticals to Acquire Kezar, Expanding Autoimmune Pipeline - tipranks.com
Aurinia (NASDAQ: AUPH) to acquire Kezar with $6.955 per share cash and CVRs - Stock Titan
Kezar Life Sciences' Christopher J. Kirk, Marc L. Belsky and Mark Schiller to Depart under Separation Agreements - TradingView
Aurinia to acquire Kezar (NASDAQ: KZR) for $6.955 cash plus CVR - Stock Titan
KZR Technical Analysis & Stock Price Forecast - Intellectia AI
Major Kezar (KZR) shareholder signs merger support pact and drops bid - Stock Titan
Aurinia Pharmaceuticals: $6.955 Per Share Acquisition Of Kezar Life Sciences To Expand Autoimmune Pipeline - Pulse 2.0
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right - Zenopa
Trend Recap: What is Kezar Life Sciences Incs market position2026 Chart Watch & Real-Time Stock Price Movement Reports - baoquankhu1.vn
Aurinia to acquire Kezar Life Sciences - The Pharma Letter
Are KZR, NSA, EQH, CTRA Obtaining Fair Deals for their Shareholders? - Sahm
KZR Acquisition by Aurinia Pharmaceuticals Valued at $6.955 per Share - GuruFocus
Aurinia to Acquire Kezar Life Sciences (KZR) in Cash Deal - GuruFocus
Aurinia to Acquire Kezar Life Sciences (KZR) in Strategic Deal - GuruFocus
Jefferies maintains Kezar Life Sciences stock rating on acquisition By Investing.com - Investing.com India
Jefferies maintains Kezar Life Sciences stock rating on acquisition - Investing.com
After failed takeover bid, activist investor finds new way to buy out Bay Area company - The Business Journals
Aurinia Pharma U.S., Inc. agreed to acquire Kezar Life Sciences, Inc. for $51 million. - MarketScreener
Shareholder Alert: The Ademi Firm investigates whether Kezar Lif - GuruFocus
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Kezar Life Sciences, Inc. (NASDAQ: KZR) - PR Newswire
US Market Wrap: Does Kezar Life Sciences Inc meet Warren Buffetts criteria2026 Macro Moves & Consistent Return Investment Signals - baoquankhu1.vn
Aurinia to acquire Kezar Life Sciences for $6.955 per share By Investing.com - Investing.com South Africa
The Ademi Firm Investigates Whether Kezar Life Sciences, Inc. Is Obtaining a Fair Price for Public Shareholders - Moomoo
Aurinia Pharmaceuticals Acquires Kezar Life Sciences - Contract Pharma
Aurinia to Buy Kezar Life Sciences in Cash-and-CVR Autoimmune Deal - tipranks.com
Kezar Life Sciences stock jumps on Aurinia acquisition deal By Investing.com - Investing.com Australia
Kezar Life Sciences stock jumps on Aurinia acquisition deal - Investing.com
Kezar Life Sciences to Be Acquired by Aurinia in $6.955-Per-Share Cash Tender Offer Plus CVR - TradingView
Aurinia (NASDAQ: AUPH) to buy Kezar (NASDAQ: KZR) for $6.955 plus CVR - Stock Titan
KZR Stock Alert: Halper Sadeh LLC is Investigating Whether Kezar Life Sciences, Inc. is Obtaining a Fair Price for its Shareholders - The Joplin Globe
Aurinia to acquire Kezar Life Sciences for $6.955 per share - Investing.com
What is the next catalyst for Kezar Life Sciences Inc2026 Earnings Impact & Fast Moving Market Watchlists - baoquankhu1.vn
Kezar Life Sciences 2025 Annual Report: Strategic Alternatives, Clinical Pipeline, and Key Risks - Minichart
KZR: Net loss narrowed to $56M in 2025 as restructuring and strategic review efforts continued - TradingView
[10-K] Kezar Life Sciences, Inc. Files Annual Report - Stock Titan
Kezar Life Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Kezar Life Sciences (KZR) to Release Earnings on Tuesday - Defense World
Highs Report: Can Kezar Life Sciences Inc maintain its current growth rate2026 Key Highlights & Weekly Breakout Watchlists - baoquankhu1.vn
If You Invested $1,000 in Kezar Life Sciences (KZR) - Stock Titan
Bull Bear: Is EEIQ still a buy after recent gains2026 Big Picture & Expert Curated Trade Setup Alerts - baoquankhu1.vn
Analyst Downgrade: Is Kezar Life Sciences Inc undervalued by DCF analysis2026 Retail Activity & Daily Market Momentum Tracking - baoquankhu1.vn
Kezar Life Sciences Inc expected to post a loss of $1.23 a shareEarnings Preview - TradingView
Kezar Life Sciences, Inc.: Fundamental Analysis and Financial Ratings | 2KZ0 | US49372L2097 - marketscreener.com
Enodia jumps ahead in Sec61 targeting, adds Kezar’s program - BioWorld MedTech
Kezar Life Sciences Inc Azioni (KZR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):